Core Viewpoint - Eddie Pharmaceuticals (688488.SH) expects a significant reduction in losses for the fiscal year 2025, with projected revenues increasing substantially compared to the previous year [1] Financial Performance - The company anticipates total revenue for 2025 to be approximately 721.01 million yuan, an increase of about 303.21 million yuan or 72.57% year-on-year [1] - Revenue from innovative anti-HIV drugs is expected to reach approximately 285.31 million yuan, reflecting a year-on-year increase of 90.34% [1] - The revenue from the subsidiary Nanjing Nanda Pharmaceutical Co., Ltd. is projected to be around 299.84 million yuan, with a year-on-year increase of 227.38% [1] Profitability Outlook - The company forecasts a net loss attributable to shareholders of approximately 16.00 million to 24.00 million yuan for 2025, which represents a reduction in losses of about 125.20 million to 117.20 million yuan, translating to a year-on-year decrease in loss margin of approximately 88.67% to 83.00% [1] - The expected net loss attributable to shareholders, excluding non-recurring gains and losses, is projected to be around 17.20 million to 25.20 million yuan, indicating a reduction in losses of approximately 131.25 million to 123.25 million yuan, with a year-on-year decrease in loss margin of about 88.41% to 83.02% [1]

Core Viewpoint - The company, Aidi Pharmaceutical (688488.SH), anticipates a significant increase in revenue for the fiscal year 2025, with a projected total revenue of approximately 721.01 million yuan, representing a year-on-year increase of about 72.57% [1] Revenue Projections - The expected revenue from innovative anti-HIV drugs is projected to be approximately 285.31 million yuan, reflecting a year-on-year increase of 90.34% [1] - The revenue from the subsidiary, Nanjing Nanda Pharmaceutical Co., Ltd., is expected to reach approximately 299.84 million yuan, with a year-on-year increase of 227.38% [1] Profitability Outlook - The company forecasts a net loss attributable to shareholders of approximately 16 million to 24 million yuan for 2025, which is a reduction in loss of about 125.20 million to 117.20 million yuan compared to the previous year, resulting in a year-on-year decrease in loss margin of approximately 88.67% to 83.00% [1] - The expected net loss attributable to shareholders, excluding non-recurring gains and losses, is projected to be around 17.20 million to 25.20 million yuan, indicating a reduction in loss of approximately 131.25 million to 123.25 million yuan compared to the previous year, with a year-on-year decrease in loss margin of about 88.41% to 83.02% [1]

Core Viewpoint - The company anticipates a significant increase in revenue for the fiscal year 2025, driven by its innovative HIV drug and the performance of Nanda Pharmaceutical, despite projected net losses narrowing compared to the previous year [1] Revenue Projections - The company expects total revenue of approximately 721.01 million yuan for 2025, representing a year-on-year increase of about 72.57% [1] - Revenue from the innovative HIV drug is projected to be around 285.31 million yuan, reflecting a year-on-year growth of 90.34% [1] - Nanda Pharmaceutical's revenue is expected to reach approximately 299.84 million yuan, with a consolidated year-on-year increase of 227.38% [1] Profitability Outlook - The net profit attributable to the parent company is projected to be between -16 million yuan and -24 million yuan, indicating a year-on-year reduction in loss margin by approximately 88.67% to 83.00% [1] - The non-recurring net profit is expected to range from -17.2 million yuan to -25.2 million yuan, with a year-on-year decrease in loss margin of about 88.41% to 83.02% [1] - The improvement in profitability is primarily attributed to an increase in gross margin from core business operations, despite a rise in selling expenses [1]

艾迪药业公告，公司及全资子公司泸州艾迪医药技术有限公司于近日收到国家药品监督管理局签发的境 内生产药品注册临床试验的《受理通知书》。产品名称为ACC085注射液，适应症为用于有 HIV-1感染 风险的成人和体重至少35kg青少年进行暴露前预防(PrEP)的 HIV-1衣壳抑制剂。 ...

融资余额降幅前20只个股 证券时报·数据宝统计显示，截至1月22日，沪市两融余额13767.95亿元，较前一交易日增加21.87亿元； 深市两融余额13391.33亿元，较前一交易日增加17.66亿元；北交所两融余额89.85亿元，较前一交易日 减少0.62亿元；深沪北两融余额合计27249.13亿元，较前一交易日增加38.90亿元。 具体到个股来看，融资余额出现增长的股票有1756只，占比46.55%，其中，311股融资余额增幅超过5% 。融资余额增幅最大的是中超控股，该股最新融资余额6.12亿元，较前一交易日增幅达119.34%；股价 表现上，该股当日上涨10.04%，表现强于沪指；融资余额增幅较多的还有华新精科、潍柴重机，融资 余额增幅分别为57.00%、51.33%。 融资余额增幅前20只个股中，从市场表现来看，平均上涨6.95%，涨幅居前的有特瑞斯、三角防务、富 满微，涨幅分别为29.98%、19.99%、15.19%。跌幅居前的有聚胶股份、广钢气体、汇隆活塞，跌幅分 别为8.16%、6.44%、5.05%。 融资余额增幅前20只个股 | 代码 | 简称 | 最新融资余额（万 | 较前一个交易日增减 ...

Market Overview - The biopharmaceutical sector experienced a decline of 0.73% on January 22, with Aidi Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 4122.58, up 0.14%, while the Shenzhen Component Index closed at 14327.05, up 0.5% [1] Individual Stock Performance - Wanze Co., Ltd. (000534) saw a significant increase of 6.53%, closing at 27.74 with a trading volume of 337,600 shares and a transaction value of 917 million [1] - Aidi Pharmaceutical (688488) reported a substantial decrease of 13.48%, closing at 18.17 with a trading volume of 281,700 shares and a transaction value of 537 million [2] - Other notable performers included ST Sihuan (000518) with a rise of 3.03% and Kanghong Pharmaceutical (002773) with a decline of 3.03% [1][2] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 551 million from institutional investors, while retail investors saw a net inflow of 279 million [2] - The main capital inflow was observed in Wanze Co., Ltd. with 81.16 million from institutional investors, while Kanghong Pharmaceutical had a net outflow of 50.59 million from retail investors [3]

Group 1 - The A-share market saw a significant decline in innovative drug concept stocks, with notable drops including Aidi Pharmaceutical down over 11% and Yifang Bio down over 5% [1] - Other companies such as Xingqi Pharmaceutical, Zhenbaodao, and Dize Pharmaceutical experienced declines of over 4%, while Rongchang Bio, Hanshang Group, Yuekang Pharmaceutical, Xinlitai, Haishike, Shanghai Yizhong, and Kanghong Pharmaceutical fell by over 3% [1] Group 2 - Aidi Pharmaceutical (688488) reported a decline of 11.33%, with a total market value of 7.835 billion and a year-to-date increase of 14.02% [2] - Yifang Bio (688382) decreased by 5.99%, with a market capitalization of 15 billion and a year-to-date decline of 4.99% [2] - Xingqi Pharmaceutical (300573) fell by 4.82%, with a market value of 19.4 billion and a year-to-date increase of 12.01% [2] - Zhenbaodao (603567) dropped by 4.74%, with a market capitalization of 7.951 billion and a year-to-date decline of 5.38% [2] - Dize Pharmaceutical (688192) decreased by 4.19%, with a market value of 27.5 billion and a year-to-date increase of 2.78% [2] - Rongchang Bio (688331) fell by 3.98%, with a market capitalization of 56.1 billion and a year-to-date increase of 27.79% [2] - Hanshang Group (600774) decreased by 3.93%, with a market value of 3.101 billion and a year-to-date increase of 14.99% [2] - Yuekang Pharmaceutical (688658) dropped by 3.84%, with a market capitalization of 12 billion and a year-to-date increase of 18.40% [2] - Xinlitai (002294) fell by 3.32%, with a market value of 55.5 billion and a year-to-date increase of 0.48% [2] - Haishike (002653) decreased by 3.23%, with a market capitalization of 56.1 billion and a year-to-date decline of 2.44% [2] - Shanghai Yizhong (688091) dropped by 3.17%, with a market value of 11.2 billion and a year-to-date increase of 15.60% [2] - Kanghong Pharmaceutical (002773) fell by 3.15%, with a market capitalization of 29.5 billion and a year-to-date increase of 6.81% [2]

本报记者 曹卫新 开年以来，上市公司并购重组积极性持续升温。在政策引导与资本加持的双重作用下，市场资源正加速 向战略性新兴产业集中。据Wind资讯数据统计，按首次披露日期计，1月1日至21日，A股市场累计披露 240起并购重组事件。其中，10单涉及重大资产重组。 据和利时电机官网信息，该公司成立于1995年，20余年来一直专注于电机、驱动器及控制系统的研发， 靠过硬的产品品质及给用户的优质服务和技术支持赢得了用户的口碑及信赖。公司自主研制的步进电机 及驱动器、交流伺服电机及驱动器、无刷直流电机及驱动器三大系列核心产品（100余种驱动器，近500 种电机）已经占据国内市场的相当份额，销售收入每年平均增长率达到20%。 除高端制造领域外，医药行业的并购重组也较为活跃。例如，1月14日，江苏艾迪药业集团股份有限公 司发布公告称，公司拟向不超过35名特定投资者发行股份募集资金总额不超过1.85亿元，用于收购南京 南大药业有限责任公司（以下简称"南大药业"）22.23%股权及补充流动资金。收购完成后，公司对南大 药业的直接持股比例将由51.13%增加至73.36%。 深度科技研究院院长张孝荣对《证券日报》记者表示，战略 ...

Group 1 - The biopharmaceutical sector increased by 0.19% on January 21, with Nearshore Protein leading the gains [1] - The Shanghai Composite Index closed at 4116.94, up 0.08%, while the Shenzhen Component Index closed at 14255.12, up 0.7% [1] - Key stocks in the biopharmaceutical sector showed significant price increases, with Nearshore Protein rising by 6.37% to a closing price of 48.76 [1] Group 2 - The biopharmaceutical sector experienced a net inflow of 77.04 million yuan from institutional investors, while retail investors saw a net outflow of 284 million yuan [2] - Major stocks like Watson Bio and Ganli Pharmaceutical attracted significant institutional investment, with net inflows of 64.45 million yuan and 55.25 million yuan, respectively [3] - Retail investors showed a negative trend in several stocks, with Watson Bio and Ganli Pharmaceutical experiencing net outflows of 33.30 million yuan and 39.14 million yuan, respectively [3]

（文章来源：北京商报） 公告显示，多替拉韦拉米夫定替诺福韦片是由公司开发的用于治疗HIV-1感染的化学药品2.3类复方制 剂。 北京商报讯1月19日晚间，艾迪药业（688488）发布公告称，公司收到国家药品监督管理局于1月18日核 准签发的《药物临床试验批准通知书》，同意公司抗艾滋病领域在研2.3类改良型新药多替拉韦拉米夫 定替诺福韦片（ADC205片）开展临床试验。 ...